Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA2 | P47869 | 4/20 | 0.50 |
| ▸ | GABRB2 | P47870 | 4/20 | 0.50 |
| ▸ | GGPS1 | O95749 | 3/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | MIF | P14174 | 1/20 | 0.42 |
| ▸ | CYP19A1 | P11511 | 9/20 | 0.41 |
| ▸ | DDX3X | O00571 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18767836 | 0.82 | GABRA2 (0.49) | GABRA2GABRB2GGPS1MIFCYP19A1 | |
| SCHEMBL24023219 | 0.81 | GABRA2 (0.33) | GABRA2GABRB2 | |
| SCHEMBL14212090 | 0.77 | GABRA2 (0.38) | GABRA2GABRB2GGPS1L3MBTL1MIF | |
| SCHEMBL15222209 | 0.76 | GABRA2 (0.45) | GABRA2GABRB2GGPS1L3MBTL1MIF | |
| SCHEMBL14681096 | 0.73 | L3MBTL1 (0.46) | GABRA2GABRB2GGPS1L3MBTL1MIF | |
| SCHEMBL23265089 | 0.72 | L3MBTL1 (0.45) | GABRA2GABRB2GGPS1L3MBTL1MIF | |
| SCHEMBL5021080 | 0.72 | L3MBTL1 (0.56) | GGPS1L3MBTL1MIFCYP19A1 | |
| SCHEMBL20812235 | 0.71 | NOTUM (0.44) | GABRA2GABRB2GGPS1MIFCYP19A1 | |
| SCHEMBL5020804 | 0.70 | HRH4 (0.58) | GGPS1L3MBTL1CYP19A1 | |
| SCHEMBL3560938 | 0.70 | L3MBTL1 (0.55) | GGPS1L3MBTL1CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190161452-A1 | Process for the preparation of azidoperfluoroalkanes and N-polyfluoroalkyl azides | USTAV ORGANICKE CHEMIE A BIOCHEMIE AV CR, V.V.I. (CZ) | 2019-05-30 | — | — | US | claimed |
| US-10590091-B2 | Process for the preparation of azidoperfluoroalkanes and N-polyfluoroalkyl azides | Ustav Organicke Chemie A Biochemie AV CR , v.v.i. (CZ) | 2020-03-17 | — | — | US | disclosed |
| US-20190161452-A1 | Process for the preparation of azidoperfluoroalkanes and N-polyfluoroalkyl azides | USTAV ORGANICKE CHEMIE A BIOCHEMIE AV CR, V.V.I. (CZ) | 2019-05-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10590091-B2 | Process for the preparation of azidoperfluoroalkanes and N-polyfluoroalkyl azides | CYP2F1, PRXL2A, CRBN | GABRA2 805/4885GABRB2 1060/4885GGPS1 4026/4885 |
| US-20190161452-A1 | Process for the preparation of azidoperfluoroalkanes and N-polyfluoroalkyl azides | CYP2F1, PRXL2A, CRBN | GABRA2 805/4885GABRB2 1060/4885GGPS1 4026/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.